The Brexit vote brings immediate uncertainty to the pharmaceutical industry, in terms of export (the EU accounts for 56% of UK pharma exports) and regulation — of intellectual property rights, clinical trials, quality standards, and drug and devices approvals. While individual countries do have approval systems in place, as well as country rules over pricing and reimbursement, pharmaceutical companies see the harmonisation of approvals afforded by the European Medicines Agency (EMA) as a means of containing costs.
Edelman has prepared a full briefing on the implications of Brexit for the Health sector, to read it please click here.
Originally published at www.edelman.co.uk.
